Home › Encyclopedia › Albiglutide: Research Status, Identity, and Trial Data
Research / Unapproved

Albiglutide: Research Status, Identity, and Trial Data

Molecular formulaC148H223N39O46
Molecular weight3284.6 g/mol
Registered trials39
PubChem CID122173812

What Albiglutide Is

Albiglutide is a large peptide compound with the molecular formula C148H223N39O46 and a molecular weight of approximately 3284.6 g/mol (PubChem CID 122173812). No approved drug label is currently associated with this compound in the data reviewed here. Any discussion of its biological activity, structure, or pharmacology in this profile is limited strictly to identity information, not clinical application.

Trial Footprint

Albiglutide has been registered in 39 clinical trials. Among the studies on record, one Phase 1 trial examined gastric emptying via scintigraphy in healthy subjects compared with placebo and was completed. A Phase 3 trial assessing safety and efficacy in people with type 2 diabetes was also completed. A separate Phase 4 extension study evaluating long-term safety, tolerability, and pharmacodynamics in type 2 diabetes mellitus subjects was terminated. These entries reflect the scope and status of registered research, not conclusions about safety or effectiveness.

FAQ

Is albiglutide approved for medical use?
This profile does not identify an approved drug label for albiglutide. The information here reflects only its chemical identity and registered clinical trial activity, not an approval status determination.
What is albiglutide made of?
Albiglutide is a peptide compound with the molecular formula C148H223N39O46 and a molecular weight of about 3284.6 g/mol. It is catalogued under PubChem CID 122173812.
How many clinical trials have studied albiglutide?
Albiglutide appears in 39 registered clinical trials. These span different phases and statuses, including completed and terminated studies.
What kinds of studies have been conducted on albiglutide?
Sample trials include an early-phase study on gastric emptying in healthy subjects, a Phase 3 safety and efficacy study in people with type 2 diabetes, and a Phase 4 extension study on long-term safety that was later terminated. These examples illustrate the range of research registered for this compound.
Were there any reported side effects for albiglutide in this data set?
No adverse event report data was available in the data reviewed for this profile. This profile does not include a side effects summary as a result.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07